Benzinga's Top Initiations

Analysts at Stifel Nicolaus initiated coverage on shares of Dicerna Pharmaceuticals (NASDAQ: DRNA ) with a “buy” rating. The target price for Dicerna Pharmaceuticals is set to $53. Dicerna Pharmaceuticals' shares closed at $39.50 on Friday. KLR Group initiated coverage on shares of Noble Energy (NYSE: NBL ) with